![Sophie Smart BSc, MSc, PhD, FHEA](https://profiles-cardiff.imgix.net/attachments/3648?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Sophie Smart
(hi/ei)
BSc, MSc, PhD, FHEA
Timau a rolau for Sophie Smart
Cydymaith Ymchwil, Is-adran Meddygaeth Seicolegol a Niwrowyddorau Clinigol
Trosolwyg
Rwy'n Gydymaith Ymchwil Ôl-ddoethurol wedi'i leoli yn y grŵp ymchwil seicosis, o fewn y Ganolfan Geneteg a Genomeg Niwroseiciatrig (Is-adran Meddygaeth Seicolegol a Niwrowyddorau Clinigol). Fel ymchwilydd sy'n arbenigo mewn sgitsoffrenia, geneteg, a methodoleg epidemiolegol, mae gen i ddiddordeb mewn dod o hyd i ffyrdd o adnabod is-grwpiau o bobl â seicosis fel y gallant elwa o ofal iechyd mwy wedi'i deilwra.
Ar hyn o bryd rwy'n gweithio ar Grant Rhaglen MRC o'r enw prosiect Genetics to Improve Outcomes in Schizophrenia (GENios). Mae hyn yn dilyn gwaith rydw i wedi'i wneud o'r blaen fel rhan o brosiect a ariennir gan yr UE i ddefnyddio data byd go iawn i wella canlyniadau a chydweithrediad darganfod cyffuriau a ariennir gan fferyllol.
Cyhoeddiad
2025
- Koch, E. et al. 2025. Recommendations for defining treatment outcomes in major psychiatric disorders using real-world data. The Lancet Psychiatry 12(6), pp. 457-468. (10.1016/S2215-0366(25)00061-6)
- Kappel, D., Smart, S., Owen, M., O'Donovan, M., Pardiñas, A. and Walters, J. 2025. Association between genetic liability to physical health conditions and comorbidities in individuals with severe mental illness: an analysis of two cross-sectional observational studies in the UK. The Lancet Psychiatry 12(6), pp. 447-456. (10.1016/S2215-0366(25)00123-3)
- Smart, S. E. et al. 2025. The role of SLC39A8.p.( Ala391Thr ) in schizophrenia symptom severity and cognitive ability: cross‐sectional studies of schizophrenia and the general UK population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, article number: e33037. (10.1002/ajmg.b.33037)
2024
- Owen, D., Lynham, A. J., Smart, S. E., Pardiñas, A. F. and Camacho Collados, J. 2024. AI for analyzing mental health disorders among social media users: Quarter-century narrative review of progress and challenges. Journal of Medical Internet Research 26, article number: e59225. (10.2196/59225)
- Woolway, G. E. et al. 2024. Assessing the validity of a self-reported clinical diagnosis of schizophrenia. Schizophrenia 10(1), article number: 99. (10.1038/s41537-024-00526-5)
2023
- Griffiths, K. et al. 2023. Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophrenia. Schizophrenia Research 260, pp. 152-159. (10.1016/j.schres.2023.08.020)
- Smart, S. E., Dimes, H., Lumley, C., Spooner, S., Anderson, S., Platt, S. and Davidson, S. 2023. A volunteer-run, face-to-face, early intervention service for reducing suicidality: a service evaluation of the listening place. Crisis: The Journal of Crisis Intervention and Suicide Prevention 44(4), pp. 349-360. (10.1027/0227-5910/a000879)
- Millgate, E. et al. 2023. Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study. Schizophrenia Research 255, pp. 173-181. (10.1016/j.schres.2023.03.020)
2022
- Pistis, G. et al. 2022. Gene set enrichment analysis of pathophysiological pathways highlights oxidative stress in psychosis. Molecular Psychiatry 27, pp. 5135-5143. (10.1038/s41380-022-01779-1)
- Smart, S. E. et al. 2022. Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium. Schizophrenia Research 250, pp. 1-9. (10.1016/j.schres.2022.09.009)
- Millgate, E. et al. 2022. Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study. BMJ Open 12(11), article number: e062570. (10.1136/bmjopen-2022-062570)
- Fonseca de Freitas, D. et al. 2022. Clinical correlates of early onset antipsychotic treatment resistance. Journal of Psychopharmacology 36(11), pp. 1226-1233. (10.1177/02698811221132537)
- Woolway, G. et al. 2022. Schizophrenia polygenic risk and experiences of childhood adversity: a systematic review and meta-analysis. Schizophrenia Bulletin 48(5), pp. 967-980. (10.1093/schbul/sbac049)
- Kadra-Scalzo, G. et al. 2022. A predictor model of treatment resistance in schizophrenia using data from electronic health records. PLoS ONE 17(9), article number: e0274864. (10.1371/journal.pone.0274864)
- Fonseca de Freitas, D. et al. 2022. Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine. Journal of Psychopharmacology 36(4), pp. 498-506. (10.1177/02698811221078746)
- Siskind, D. et al. 2022. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. British Journal of Psychiatry 220(3), pp. 115-120. (10.1192/bjp.2021.61)
- Pardinas, A. et al. 2022. Interaction testing and polygenic risk scoring to estimate the contribution of common genetic variants to treatment resistance in schizophrenia. JAMA Psychiatry 79(3), pp. 260-269. (10.1001/jamapsychiatry.2021.3799)
2021
- Homman, L. E., Smart, S. E., O'Neill, F. and MacCabe, J. H. 2021. Attrition in longitudinal studies among patients with schizophrenia and other psychoses; findings from the STRATA collaboration. Psychiatry Research 305, article number: 114211. (10.1016/j.psychres.2021.114211)
- Gifford, G. et al. 2021. Integrated metastate functional connectivity networks predict change in symptom severity in clinical high risk for psychosis. Human Brain Mapping 42(2), pp. 439-451. (10.1002/hbm.25235)
- Smart, S. E., Kepinska, A. P., Murray, R. M. and MacCabe, J. H. 2021. Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies. Psychological Medicine 51(1), pp. 44-53. (10.1017/S0033291719002083)
2020
- McGuire, P. et al. 2020. Neural circuitry of novelty salience processing in psychosis risk: association with clinical outcome. Schizophrenia Bulletin 46(3), pp. 670-679. (10.1093/schbul/sbz089)
2018
- Kravariti, E. et al. 2018. Applying the Higher Education Academy framework for partnership in learning and teaching in higher education to online partnership learning communities: a case atudy and an extended model. Teaching & Learning Inquiry: The ISSOTL Journal 6(2), pp. 143-164. (10.20343/teachlearninqu.6.2.11)
Articles
- Koch, E. et al. 2025. Recommendations for defining treatment outcomes in major psychiatric disorders using real-world data. The Lancet Psychiatry 12(6), pp. 457-468. (10.1016/S2215-0366(25)00061-6)
- Kappel, D., Smart, S., Owen, M., O'Donovan, M., Pardiñas, A. and Walters, J. 2025. Association between genetic liability to physical health conditions and comorbidities in individuals with severe mental illness: an analysis of two cross-sectional observational studies in the UK. The Lancet Psychiatry 12(6), pp. 447-456. (10.1016/S2215-0366(25)00123-3)
- Smart, S. E. et al. 2025. The role of SLC39A8.p.( Ala391Thr ) in schizophrenia symptom severity and cognitive ability: cross‐sectional studies of schizophrenia and the general UK population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, article number: e33037. (10.1002/ajmg.b.33037)
- Owen, D., Lynham, A. J., Smart, S. E., Pardiñas, A. F. and Camacho Collados, J. 2024. AI for analyzing mental health disorders among social media users: Quarter-century narrative review of progress and challenges. Journal of Medical Internet Research 26, article number: e59225. (10.2196/59225)
- Woolway, G. E. et al. 2024. Assessing the validity of a self-reported clinical diagnosis of schizophrenia. Schizophrenia 10(1), article number: 99. (10.1038/s41537-024-00526-5)
- Griffiths, K. et al. 2023. Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophrenia. Schizophrenia Research 260, pp. 152-159. (10.1016/j.schres.2023.08.020)
- Smart, S. E., Dimes, H., Lumley, C., Spooner, S., Anderson, S., Platt, S. and Davidson, S. 2023. A volunteer-run, face-to-face, early intervention service for reducing suicidality: a service evaluation of the listening place. Crisis: The Journal of Crisis Intervention and Suicide Prevention 44(4), pp. 349-360. (10.1027/0227-5910/a000879)
- Millgate, E. et al. 2023. Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study. Schizophrenia Research 255, pp. 173-181. (10.1016/j.schres.2023.03.020)
- Pistis, G. et al. 2022. Gene set enrichment analysis of pathophysiological pathways highlights oxidative stress in psychosis. Molecular Psychiatry 27, pp. 5135-5143. (10.1038/s41380-022-01779-1)
- Smart, S. E. et al. 2022. Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium. Schizophrenia Research 250, pp. 1-9. (10.1016/j.schres.2022.09.009)
- Millgate, E. et al. 2022. Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study. BMJ Open 12(11), article number: e062570. (10.1136/bmjopen-2022-062570)
- Fonseca de Freitas, D. et al. 2022. Clinical correlates of early onset antipsychotic treatment resistance. Journal of Psychopharmacology 36(11), pp. 1226-1233. (10.1177/02698811221132537)
- Woolway, G. et al. 2022. Schizophrenia polygenic risk and experiences of childhood adversity: a systematic review and meta-analysis. Schizophrenia Bulletin 48(5), pp. 967-980. (10.1093/schbul/sbac049)
- Kadra-Scalzo, G. et al. 2022. A predictor model of treatment resistance in schizophrenia using data from electronic health records. PLoS ONE 17(9), article number: e0274864. (10.1371/journal.pone.0274864)
- Fonseca de Freitas, D. et al. 2022. Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine. Journal of Psychopharmacology 36(4), pp. 498-506. (10.1177/02698811221078746)
- Siskind, D. et al. 2022. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. British Journal of Psychiatry 220(3), pp. 115-120. (10.1192/bjp.2021.61)
- Pardinas, A. et al. 2022. Interaction testing and polygenic risk scoring to estimate the contribution of common genetic variants to treatment resistance in schizophrenia. JAMA Psychiatry 79(3), pp. 260-269. (10.1001/jamapsychiatry.2021.3799)
- Homman, L. E., Smart, S. E., O'Neill, F. and MacCabe, J. H. 2021. Attrition in longitudinal studies among patients with schizophrenia and other psychoses; findings from the STRATA collaboration. Psychiatry Research 305, article number: 114211. (10.1016/j.psychres.2021.114211)
- Gifford, G. et al. 2021. Integrated metastate functional connectivity networks predict change in symptom severity in clinical high risk for psychosis. Human Brain Mapping 42(2), pp. 439-451. (10.1002/hbm.25235)
- Smart, S. E., Kepinska, A. P., Murray, R. M. and MacCabe, J. H. 2021. Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies. Psychological Medicine 51(1), pp. 44-53. (10.1017/S0033291719002083)
- McGuire, P. et al. 2020. Neural circuitry of novelty salience processing in psychosis risk: association with clinical outcome. Schizophrenia Bulletin 46(3), pp. 670-679. (10.1093/schbul/sbz089)
- Kravariti, E. et al. 2018. Applying the Higher Education Academy framework for partnership in learning and teaching in higher education to online partnership learning communities: a case atudy and an extended model. Teaching & Learning Inquiry: The ISSOTL Journal 6(2), pp. 143-164. (10.20343/teachlearninqu.6.2.11)
Ymchwil
Fel ymchwilydd sy'n arbenigo mewn sgitsoffrenia a methodoleg epidemiolegol, mae gen i ddiddordeb mewn dod o hyd i ffyrdd o adnabod is-grwpiau o bobl â seicosis fel y gallant elwa o ofal iechyd mwy wedi'i deilwra. Rwy'n angerddol am ddarparu profiad ymchwil rhagorol i gyfranogwyr, dilyn gwyddoniaeth dryloyw, a defnyddio fy ngwybodaeth o ddylunio ac ystadegau ymchwil i wella'r broses wyddonol.
Addysgu
Ym mis Mai 2025 deuthum yn Gymrawd AdvanceHE (FHEA). Rwy'n addysgu dulliau ymchwil epidemiolegol ac ystadegau ar y cyrsiau ôl-raddedig a addysgir Biowybodeg a Genomeg Gymhwysol a Genomeg (MSc) a Biowybodeg Gymhwysol ac Epidemioleg Genetig (MSc).
Bywgraffiad
Ar ôl gradd israddedig mewn seicoleg a gradd meistr mewn ymchwil seiciatrig, dechreuais weithio fel cynorthwyydd ymchwil yn y Sefydliad Seiciatreg, Seicoleg a Niwrowyddoniaeth (IoPPN). Arhosais yno am dros 4 blynedd, gan weithio ar wahanol astudiaethau sy'n cynnwys cyfranogwyr â sgitsoffrenia. Yn ystod fy mlynyddoedd yn yr IoPPN y cwblheais PhD yn rhan-amser.
Ym mis Ionawr 2020, ymunais â'r grŵp ymchwil seicosis yn y Ganolfan Geneteg a Genomeg Niwroseiciatrig, Is-adran Meddygaeth Seicolegol a Niwrowyddorau Clinigol.
Y tu allan i'r gwaith, rwy'n gwirfoddoli i elusen o'r enw The Listening Place (TLP) drwy oruchwylio eu gwerthusiadau gwasanaeth. Mae TLP yn darparu cefnogaeth wyneb yn wyneb, gan wirfoddolwyr hyfforddedig, i bobl nad ydynt bellach yn teimlo bod bywyd yn werth ei fyw.
Safleoedd academaidd blaenorol
- 2020-presennol: Cyswllt Ymchwil Ôl-ddoethurol, Canolfan Geneteg a Genomeg Niwroseiciatrig, Is-adran Meddygaeth Seicolegol a Niwrowyddorau Clinigol, Prifysgol Caerdydd
- 2016-2019: Myfyriwr PhD, Adran Astudiaethau Seicosis, Sefydliad Seiciatreg, Seicoleg a Niwrowyddoniaeth, Coleg y Brenin Llundain
- 2015-2019: Gweithiwr Ymchwil, Adran Astudiaethau Seicosis, Sefydliad Seiciatreg, Seicoleg a Niwrowyddoniaeth, Coleg y Brenin Llundain
Contact Details
Themâu ymchwil
Arbenigeddau
- Iechyd Meddwl
- Geneteg Seiciatrig
- Geneteg ystadegol a meintiol
- Epidemioleg